A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

NCT07485920 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Interventions

DRUG: Tislelizumab and nintedanib

Sponsor

The Affiliated Hospital of Qingdao University